The immunology of macrophage activation syndrome

Frontiers in Immunology

Volumn 10, Issue FEB, 2019, Pages

  Crayne, Courtney B ^a   Albeituni, Sabrin ^b   Nichols, Kim E ^b   Cron, Randy Q ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Anakinra; Cytokine storm; Hemophagocytic lymphohistiocytosis; IL 1; IL 18; IL 6; Macrophage activation syndrome; NK cell

Indexed keywords

2 AMINO 3 PHOSPHONOPROPIONIC ACID; CD163 ANTIGEN; CD28 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANZYME B; HEME OXYGENASE 1; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 33; INTERLEUKIN 6; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE INHIBITOR; MUNC18 PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; PERFORIN; PERFORIN 1; RAS RELATED PROTEIN RAB 27A; SYNTAXIN; SYNTAXIN 11; SYNTAXIN BINDING PROTEIN 1; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIGEN PRESENTATION; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOINFLAMMATORY DISEASE; BLOOD CLOTTING DISORDER; CASPASE ACTIVATION AND RECRUITMENT DOMAIN; CELL INTERACTION; CYTOKINE STORM; CYTOTOXIC T LYMPHOCYTE; ERYTHROPHAGOCYTOSIS; FEVER; FIBRINOLYSIS; GENE MUTATION; GENETIC PREDISPOSITION; HEMOPHAGOCYTIC SYNDROME; HISTOPATHOLOGY; HUMAN; HYPERFERRITINEMIA; IMMUNE RESPONSE; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; JUVENILE RHEUMATOID ARTHRITIS; LIVER DYSFUNCTION; MACROPHAGE ACTIVATION; MACROPHAGE ACTIVATION SYNDROME; MULTIPLE ORGAN FAILURE; PANCYTOPENIA; PATHOGENESIS; REMISSION; REVIEW; SEPSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; CYTOTOXICITY; DENDRITIC CELL; MACROPHAGE;

ANIMALS; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HUMANS; MACROPHAGE ACTIVATION SYNDROME; MACROPHAGES;

EID: 85062103949     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2019.00119     Document Type: Review

References (128)

1. Hadchouel M, Prieur AM, Griscelli C. Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr. (1985) 106: 561-6. doi:10.1016/S0022-3476(85)80072-X
2. Stephan JL, Kone-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology (Oxford) (2001) 40: 1285-92. doi:10.1093/rheumatology/40.11.1285
3. Athreya BH Is macrophage activation syndrome a new entity? Clin Exp Rheumatol. (2002) 20: 121-3.
4. Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr. (1996) 129: 750-4. doi:10.1016/S0022-3476(96)70160-9
5. Ravelli A, Minoia F, Davi S, Horne A, Bovis F, Pistorio A, et al. 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis. (2016) 75: 481-9. doi:10.1136/annrheumdis-2015-208982
6. Ravelli A, Minoia F, Davi S, Horne A, Bovis F, Pistorio A, et al. 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. (2016) 68: 566-76. doi:10.1002/art.39332
7. Minoia F, Davi S, Horne A, Bovis F, Demirkaya E, Akikusa J, et al. Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Rheumatol. (2015) 42: 994-1001. doi:10.3899/jrheum.141261
8. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. (2007) 34: 1133-8.
9. Garcia-Pavon S, Yamazaki-Nakashimada MA, Baez M, Borjas-Aguilar KL, Murata C. Kawasaki disease complicated with macrophage activation syndrome: a systematic review. J Pediatr Hematol Oncol. (2017) 39: 445-51. doi:10.1097/MPH.0000000000000872
10. Borgia RE, Gerstein M, Levy DM, Silverman ED, Hiraki LT. Features, treatment, and outcomes of macrophage activation syndrome in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol. (2018) 70: 616-24. doi:10.1002/art.40417
11. Rigante D, Emmi G, Fastiggi M, Silvestri E, Cantarini L. Macrophage activation syndrome in the course of monogenic autoinflammatory disorders. Clin Rheumatol. (2015) 34: 1333-9. doi:10.1007/s10067-015-2923-0
12. Sepulveda FE, de Saint Basile G. Hemophagocytic syndrome: primary forms and predisposing conditions. Curr Opin Immunol. (2017) 49: 20-6. doi:10.1016/j.coi.2017.08.004
13. Tada Y, Inokuchi S, Maruyama A, Suematsu R, Sakai M, Sadanaga Y, et al. Are the 2016 EULAR/ACR/PRINTO classification criteria for macrophage activation syndrome applicable to patients with adult-onset Still's disease? Rheumatol Int. (2019) 39: 97-104. doi:10.1007/s00296-018-4114-1
14. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer (2007) 48: 124-31. doi:10.1002/pbc.21039
15. Ravelli A, De Benedetti F, Viola S, Martini A. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr. (1996) 128: 275-8. doi:10.1016/S0022-3476(96)70408-0
16. Ravelli A, Magni-Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr. (2005) 146: 598-604. doi:10.1016/j.jpeds.2004.12.016
17. Alkoht A, Hanafi I, Khalil B. Macrophage activation syndrome: a report of two cases and a literature review. Case Rep Rheumatol. (2017) 2017: 5304180. doi:10.1155/2017/5304180
18. Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. (2007) 56: 965-71. doi:10.1002/art.22416
19. Goel S, Polski JM, Imran H. Sensitivity and specificity of bone marrow hemophagocytosis in hemophagocytic lymphohistiocytosis. Ann Clin Lab Sci. (2012) 42: 21-5.
20. Ho C, Yao X, Tian L, Li FY, Podoltsev N, Xu ML. Marrow assessment for hemophagocytic lymphohistiocytosis demonstrates poor correlation with disease probability. Am J Clin Pathol. (2014) 141: 62-71. doi:10.1309/AJCPMD5TJEFOOVBW
21. Filipovich AH, Chandrakasan S. Pathogenesis of hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am. (2015) 29: 895-902. doi:10.1016/j.hoc.2015.06.007
22. Behrens EM, Cron RQ. Kill or be killed. J Immunol. (2015) 194: 5041-3. doi:10.4049/jimmunol.1500774
23. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, Bhawan S, Certain S, Mathew PA, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science (1999) 286: 1957-9. doi:10.1126/science.286.5446.1957
24. Orange JS The lytic NK cell immunological synapse and sequential steps in its formation. Adv Exp Med Biol. (2007) 601: 225-33. doi:10.1007/978-0-387-72005-0-23
25. Feldmann J, Callebaut I, Raposo G, Certain S, Bacq D, Dumont C, et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell (2003) 115: 461-73. doi:10.1016/S0092-8674(03)00855-9
26. zur Stadt U, Schmidt S, Kasper B, Beutel K, Diler AS, Henter JI, et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum Mol Genet. (2005) 14: 827-34. doi:10.1093/hmg/ddi076
27. Cote M, Menager MM, Burgess A, Mahlaoui N, Picard C, Schaffner C, et al. Munc18-2 deficienc causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells. J Clin Invest. (2009) 119: 3765-73. doi:10.1172/JCI40732
28. Rubin CM, Burke BA, McKenna RW, McClain KL, White JG, Nesbit ME, et al. The accelerated phase of Chediak-Higashi syndrome. An expression of the virus-associated hemophagocytic syndrome? Cancer (1985) 56: 524-30.
29. Menasche G, Pastural E, Feldmann J, Certain S, Ersoy F, Dupuis S, et al. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet. (2000) 25: 173-6. doi:10.1038/76024
30. Enders A, Zieger B, Schwarz K, Yoshimi A, Speckmann C, Knoepfle EM, et al. Lethal hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type II. Blood (2006) 108: 81-7. doi:10.1182/blood-2005-11-4413
31. Jenkins MR, Rudd-Schmidt JA, Lopez JA, Ramsbottom KM, Mannering SI, Andrews DM, et al Failed CTL/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time. J Exp Med. (2015) 212: 307-17. doi:10.1084/jem.20140964
32. + T cells in persistent infection with lymphocytic choriomeningitis virus. J Exp Med. (1998) 187: 1903-20.
33. Canna SW, Wrobel J, Chu N, Kreiger PA, Paessler M, Behrens EM. Interferon-γ mediates anemia but is dispensable for Fulminant Toll-Like receptor 9-induced macrophage activation syndrome and hemophagocytosis. Arthritis Rheum. (2013) 65: 1764-75. doi:10.1002/art.37958
34. Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood (2004) 104: 735-43. doi:10.1182/blood-2003-10-3413
35. Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford) (2011) 50: 417-9. doi:10.1093/rheumatology/keq218
36. De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. (2012) 367: 2385-95. doi:10.1056/NEJMoa1112802
37. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. (2014) 371: 1507-17. doi:10.1056/NEJMoa1407222
38. Canna SW, Girard C, Malle L, de Jesus A, Romberg N, Kelsen J, et al. Life-threatening NLRC4 - associated hyperinflammation successfully treated with IL-18 inhibition. J Allergy Clin Immunol. (2017) 139: 1698-701. doi:10.1016/j.jaci.2016.10.022
39. Record JL, Beukelman T, Cron RQ. Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. J Rheumatol. (2011) 38: 180-1. doi:10.3899/jrheum.100726
40. Das R, Guan P, Sprague L, Verbist K, Tedrick P, An QA, et al. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood (2016) 127: 1666-75. doi:10.1182/blood-2015-12-684399
41. Behrens EM, Canna SW, Slade K, Rao S, Kreiger PA, Paessler M, et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest. (2011) 121: 2264-77. doi:10.1172/JCI43157
42. Rood JE, Rao S, Paessler M, Kreiger PA, Chu N, Stelekati E, et al. ST2 contributes to T-cell hyperactivation and fatal hemophagocytic lymphohistiocytosis in mice. Blood (2016) 127: 426-35. doi:10.1182/blood-2015-07-659813
43. Prencipe G, Caiello I, Pascarella A, Grom AA, Bracaglia C, Chatel L, et al. Neutralization of IFN-gamma reverts clinical and laboratory features in a mouse model of macrophage activation syndrome. J Allergy Clin Immunol. (2018) 141: 1439-49. doi:10.1016/j.jaci.2017.07.021
44. Crayne CB, Cron RQ. Weathering a macrophage storm. J Rheumatol. (2017) 44: 970-2. doi:10.3899/jrheum.170370
45. Zhang M, Behrens EM, Atkinson TP, Shakoory B, Grom AA, Cron RQ. Genetic defects in cytolysis in macrophage activation syndrome. Curr Rheumatol Rep. (2014) 16: 439. doi:10.1007/s11926-014-0439-2
46. Kaufman KM, Linghu B, Szustakowski JD, Husami A, Yang F, Zhang K, et al. Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. (2014) 66: 3486-95. doi:10.1002/art.38793
47. Cichocki F, Schlums H, Li H, Stache V, Holmes T, Lenvik TR, et al. Transcriptional regulation of Munc13-4 expression in cytotoxic lymphocytes is disrupted by an intronic mutation associated with a primary immunodeficiency. J Exp Med. (2014) 211: 1079-91. doi:10.1084/jem.20131131
48. Schulert GS, Zhang M, Husami A, Fall N, Brunner H, Zhang K, et al. Brief report: novel UNC13D intronic variant disrupting an NF-kappaB enhancer in a patient with recurrent macrophage activation syndrome and systemic juvenile idiopathic arthritis. Arthritis Rheumatol. (2018) 70: 963-70. doi:10.1002/art.40438
49. Spessott WA, Sanmillan ML, McCormick ME, Patel N, Villanueva J, Zhang K, et al. Hemophagocytic lymphohistiocytosis caused by dominant-negative mutations in STXBP2 that inhibit SNARE-mediated membrane fusion. Blood (2015) 125: 1566-77. doi:10.1182/blood-2014-11-610816
50. Zhang M, Bracaglia C, Prencipe G, Bemrich-Stolz CJ, Beukelman T, Dimmitt RA, et al. A heterozygous RAB27A mutation associated with delayed cytolytic granule polarization and hemophagocytic lymphohistiocytosis. J Immunol. (2016) 196: 2492-503. doi:10.4049/jimmunol.1501284
51. Schulert GS, Zhang M, Fall N, Husami A, Kissell D, Hanosh A, et al. Whole-exome sequencing reveals mutations in genes linked to hemophagocytic lymphohistiocytosis and macrophage activation syndrome in fatal cases of H1N1 influenza. J Infect Dis. (2016) 213: 1180-8. doi:10.1093/infdis/jiv550
52. Vastert SJ, van Wijk R, D'Urbano LE, de Vooght KM, de Jager W, Ravelli A, et al. Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford) (2010) 49: 441-9. doi:10.1093/rheumatology/kep418
53. Zhang K, Biroschak J, Glass DN, Thompson SD, Finkel T, Passo MH, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum. (2008) 58: 2892-6. doi:10.1002/art.23734
54. Strippoli R, Caiello I, De Benedetti F. Reaching the threshold: a multilayer pathogenesis of macrophage activation syndrome. J Rheumatol. (2013) 40: 761-7. doi:10.3899/jrheum.121233
55. Schulert GS, Canna SW. Convergent pathways of the hyperferritinemic syndromes. Int Immunol. (2018) 30: 195-203. doi:10.1093/intimm/dxy012
56. Behrens EM Macrophage activation syndrome in rheumatic disease: what is the role of the antigen presenting cell? Autoimmun Rev. (2008) 7: 305-8. doi:10.1016/j.autrev.2007.11.025
57. Jordan MB, van Rooijen N, Izui S, Kappler J, Marrack P. Liposomal clodronate as a novel agent for treating autoimmune hemolytic anemia in a mouse model. Blood (2003) 101: 594-601. doi:10.1182/blood-2001-11-0061
58. Zoller EE, Lykens JE, Terrell CE, Aliberti J, Filipovich AH, Henson PM, et al. Hemophagocytosis causes a consumptive anemia of inflammation. J Exp Med. (2011) 208: 1203-14. doi:10.1084/jem.20102538
59. Tesi B, Sieni E, Neves C, Romano F, Cetica V, Cordeiro AI, et al. Hemophagocytic lymphohistiocytosis in 2 patients with underlying IFN-gamma receptor deficiency. J Allergy Clin Immunol. (2015) 135: 1638-41. doi:10.1016/j.jaci.2014.11.030
60. Billiau AD, Roskams T, Van Damme-Lombaerts R, Matthys P, Wouters C. Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages. Blood (2005) 105: 1648-51. doi:10.1182/blood-2004-08-2997
61. Nathan CF, Murray HW, Wiebe ME, Rubin BY. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med. (1983) 158: 670-89. doi:10.1084/jem.158.3.670
62. Murray PJ Macrophage polarization. Annu Rev Physiol. (2017) 79: 541-66. doi:10.1146/annurev-physiol-022516-034339
63. Lau SK, Chu PG, Weiss LM. CD163: a specific marker of macrophages in paraffin-embedded tissue samples. Am J Clin Pathol. (2004) 122: 794-801. doi:10.1309/QHD6YFN81KQXUUH6
64. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, et al. Identification of the haemoglobin scavenger receptor. Nature (2001) 409: 198-201. doi:10.1038/35051594
65. Avcin T, Tse SM, Schneider R, Ngan B, Silverman ED. Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J Pediatr. (2006) 148: 683-6. doi:10.1016/j.jpeds.2005.12.070
66. Ramanan AV, Grom AA. Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis? Rheumatology (Oxford) (2005) 44: 1350-3. doi:10.1093/rheumatology/keh710
67. Moller HJ, Peterslund NA, Graversen JH, Moestrup SK. Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood (2002) 99: 378-80. doi:10.1182/blood.V99.1.378
68. Droste A, Sorg C, Hogger P. Shedding of CD163, a novel regulatory mechanism for a member of the scavenger receptor cysteine-rich family. Biochem Biophys Res Commun. (1999) 256: 110-3. doi:10.1006/bbrc.1999.0294
69. Schaer DJ, Schleiffenbaum B, Kurrer M, Imhof A, Bachli E, Fehr J, et al. Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur J Haematol. (2005) 74: 6-10. doi:10.1111/j.1600-0609.2004.00318.x
70. Sakumura N, Shimizu M, Mizuta M, Inoue N, Nakagishi Y, Yachie A. Soluble CD163, a unique biomarker to evaluate the disease activity, exhibits macrophage activation in systemic juvenile idiopathic arthritis. Cytokine (2018) 110: 459-65. doi:10.1016/j.cyto.2018.05.017
71. Milner JD, Orekov T, Ward JM, Cheng L, Torres-Velez F, Junttila I, et al. Sustained IL-4 exposure leads to a novel pathway for hemophagocytosis, inflammation, and tissue macrophage accumulation. Blood (2010) 116: 2476-83. doi:10.1182/blood-2009-11-255174
72. Do T, Tan R, Bennett M, Medvedovic M, Grom AA, Shen N, et al. MicroRNA networks associated with active systemic juvenile idiopathic arthritis regulate CD163 expression and anti-inflammatory functions in macrophages through two distinct mechanisms. J Leuk Biol. (2018) 103: 71-85. doi:10.1002/JLB.2A0317-107R
73. Schaer CA, Schoedon G, Imhof A, Kurrer MO, Schaer DJ. Constitutive endocytosis of CD163 mediates hemoglobin-heme uptake and determines the noninflammatory and protective transcriptional response of macrophages to hemoglobin. Circ Res. (2006) 99: 943-50. doi:10.1161/01.RES.0000247067.34173.1b
74. Otterbein LE, Soares MP, Yamashita K, Bach FH. Heme oxygenase-1: unleashing the protective properties of heme. Trends Immunol. (2003) 24: 449-55. doi:10.1016/S1471-4906(03)00181-9
75. Minamino T, Christou H, Hsieh CM, Liu Y, Dhawan V, Abraham NG, et al. Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia. Proc Natl Acad Sci USA. (2001) 98: 8798-803. doi:10.1073/pnas.161272598
76. Vercellotti GM, Khan FB, Nguyen J, Chen C, Bruzzone CM, Bechtel H, et al. H-ferritin ferroxidase induces cytoprotective pathways and inhibits microvascular stasis in transgenic sickle mice. Front Pharmacol. (2014) 5: 79. doi:10.3389/fphar.2014.00079
77. Stout RD, Suttles J. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leuk Biol. (2004) 76: 509-13. doi:10.1189/jlb.0504272
78. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity (2014) 41: 14-20. doi:10.1016/j.immuni.2014.06.008
79. Xue J, Schmidt S, Sander J, Draffehn A, Krebs W, Quester I, et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity (2014) 40: 274-88. doi:10.1016/j.immuni.2014.01.006
80. Cron RQ, Davi S, Minoia F, Ravelli A. Clinical features and correct diagnosis of macrophage activation syndrome. Expert Rev Clin Immunol. (2015) 11: 1043-53. doi:10.1586/1744666X.2015.1058159
81. Canna SW, Behrens EM. Making Sense of the cytokine storm: a conceptual framework for understanding, diagnosing and treating hemophagocytic syndromes. Pediatr Clin North Am. (2012) 59: 329-44. doi:10.1016/j.pcl.2012.03.002
82. Kratochvill F, Neale G, Haverkamp JM, Van de Velde LA, Smith AM, Kawauchi D, et al. TNF Counterbalances the emergence of M2 tumor macrophages. Cell Rep. (2015) 12: 1902-14. doi:10.1016/j.celrep.2015.08.033
83. Harris JG, Kessler EA, Verbsky JW. Update on the treatment of juvenile idiopathic arthritis. Curr Allergy Asthma Rep. (2013) 13: 337-46. doi:10.1007/s11882-013-0351-2
84. Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatr Rheumatol Online J. (2014) 12: 13. doi:10.1186/1546-0096-12-13
85. Flammiger A, Fiedler W, Bacher U, Bokemeyer C, Schneider M, Binder M. Critical imbalance of TNF-alpha and soluble TNF receptor 1 in a patient with macrophage activation syndrome: potential implications for diagnostics and treatment. Acta Haematol. (2012) 128: 69-72. doi:10.1159/000338179
86. Sterba G, Sterba Y, Stempel C, Blank J, Azor E, Gomez L. Macrophage activation syndrome induced by etanercept in a patient with systemic sclerosis. Israel Med Assoc J. (2010) 12: 443-5.
87. Buonuomo PS, Campana A, Insalaco A, Bracaglia C, Pardeo M, Cortis E. Necrotizing fasciitis in a pediatric patient treated with etanercept and cyclosporine for macrophage activation syndrome. Rheumatol Int. (2013) 33: 1097-8. doi:10.1007/s00296-011-2319-7
88. de Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. (1991) 34: 1158-63. doi:10.1002/art.1780340912
89. Lasiglie D, Traggiai E, Federici S, Alessio M, Buoncompagni A, Accogli A, et al. Role of IL-1 beta in the development of human T(H)17 cells: lesson from NLPR3 mutated patients. PLoS ONE (2011) 6:e20014. doi:10.1371/journal.pone.0020014
90. Xu XJ, Tang YM, Song H, Yang SL, Xu WQ, Zhao N, et al. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J Pediatr. (2012) 160: 984-90.e1. doi:10.1016/j.jpeds.2011.11.046
91. Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. (2018) 24: 739-48. doi:10.1038/s41591-018-0036-4
92. Marigo I, Bosio E, Solito S, Mesa C, Fernandez A, Dolcetti L, et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity (2010) 32: 790-802. doi:10.1016/j.immuni.2010.05.010
93. Sterba Y, Ilowite N. Biologics in pediatric rheumatology: Quo Vadis? Curr Rheumatol Rep. (2016) 18: 45. doi:10.1007/s11926-016-0593-9
94. Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. (2016) 12: 259-68. doi:10.1038/nrrheum.2015.179
95. Yokota S, Itoh Y, Morio T, Sumitomo N, Daimaru K, Minota S. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab. J Rheumatol. (2015) 42: 712-22. doi:10.3899/jrheum.140288
96. Schulert GS, Minoia F, Bohnsack J, Cron RQ, Hashad S, Kon EPI, et al. Effect of biologic therapy on clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) (2018) 70: 409-19. doi:10.1002/acr.23277
97. Musso T, Espinoza-Delgado I, Pulkki K, Gusella GL, Longo DL, Varesio L. Transforming growth factor beta downregulates interleukin-1 (IL-1)-induced IL-6 production by human monocytes. Blood (1990) 76: 2466-9.
98. Netea MG, Kullberg BJ, Verschueren I, Van Der Meer JW. Interleukin-18 induces production of proinflammatory cytokines in mice: no intermediate role for the cytokines of the tumor necrosis factor family and interleukin-1beta. Eur J Immunol. (2000) 30: 3057-60. doi:10.1002/1521-4141(200010)30: 10<3057::AID-IMMU3057>3.0.CO;2-P
99. Fall N, Barnes M, Thornton S, Luyrink L, Olson J, Ilowite NT, et al. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum. (2007) 56: 3793-804. doi:10.1002/art.22981
100. Ling XB, Park JL, Carroll T, Nguyen KD, Lau K, Macaubas C, et al. Plasma profiles in active systemic juvenile idiopathic arthritis: biomarkers and biological implications. Proteomics (2010) 10: 4415-30. doi:10.1002/pmic.201000298
101. Shimizu M, Yokoyama T, Yamada K, Kaneda H, Wada H, Wada T, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology (Oxford) (2010) 49: 1645-53. doi:10.1093/rheumatology/keq133
102. Kaplanski G. Interleukin-18: Biological properties and role in disease pathogenesis. Immunol Rev. (2018) 281: 138-53. doi:10.1111/imr.12616
103. Shimizu M, Inoue N, Mizuta M, Nakagishi Y, Yachie A. Characteristic elevation of soluble TNF receptor II: I ratio in macrophage activation syndrome with systemic juvenile idiopathic arthritis. Clin Exp Immunol. (2018) 191: 349-55. doi:10.1111/cei.13026
104. Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. (2011) 63: 545-55. doi:10.1002/art.30128
105. Sonmez HE, Demir S, Bilginer Y, Ozen S. Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature. Clin Rheumatol. (2018) 37: 3329-35. doi:10.1007/s10067-018-4095-1
106. Rajasekaran S, Kruse K, Kovey K, Davis AT, Hassan NE, Ndika AN, et al. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children. Pediatr Crit Care Med. (2014) 15: 401-8. doi:10.1097/PCC.0000000000000078
107. Dinarello CA Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. (2018) 281: 8-27. doi:10.1111/imr.12621
108. Weiss ES, Girard-Guyonvarc'h C, Holzinger D, Jesus AAd, Tariq Z, Picarsic J, et al. Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. Blood (2018) 131: 1442-55. doi:10.1182/blood-2017-12-820852
109. Girard-Guyonvarc'h C, Palomo J, Martin P, Rodriguez E, Troccaz S, Palmer G, et al. Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice. Blood (2018) 131: 1430-41. doi:10.1182/blood-2017-06-789552
110. Duncan JA, Canna SW. The NLRC4 inflammasome. Immunol Rev. (2018) 281: 115-23. doi:10.1111/imr.12607
111. Barsalou J, Blincoe A, Fernandez I, Dal-Soglio D, Marchitto L, Selleri S, et al. Rapamycin as an adjunctive therapy for NLRC4 associated macrophage activation syndrome. Front Immunol. (2018) 9: 2162. doi:10.3389/fimmu.2018.02162
112. Weaver LK, Behrens EM. Hyperinflammation, rather than hemophagocytosis, is the common link between macrophage activation syndrome and hemophagocytic lymphohistiocytosis. Curr Opin Rheumatol. (2014) 26: 562-9. doi:10.1097/BOR.0000000000000093
113. Gordon S, Martinez-Pomares L. Physiological roles of macrophages. Pflugers Archiv Eur J Physiol. (2017) 469: 365-74. doi:10.1007/s00424-017-1945-7
114. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. (2005) 201: 1479-86. doi:10.1084/jem.20050473
115. Wesche H, Henzel WJ, Shillinglaw W, Li S, Cao Z. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity (1997) 7: 837-47. doi:10.1016/S1074-7613(00)80402-1
116. Muzio M, Ni J, Feng P, Dixit VM. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science (1997) 278: 1612-5. doi:10.1126/science.278.5343.1612
117. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell (1998) 2: 253-8. doi:10.1016/S1097-2765(00)80136-7
118. Krebs P, Crozat K, Popkin D, Oldstone MB, Beutler B. Disruption of MyD88 signaling suppresses hemophagocytic lymphohistiocytosis in mice. Blood (2011) 117: 6582-8. doi:10.1182/blood-2011-01-329607
119. Strippoli R, Carvello F, Scianaro R, De Pasquale L, Vivarelli M, Petrini S, et al. Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implication for the pathogenesis of macrophage activation syndrome. Arthritis Rheum. (2012) 64: 1680-8. doi:10.1002/art.33496
120. Steinman RM Decisions about dendritic cells: past present, and future. Annu Rev Immunol. (2012) 30: 1-22. doi:10.1146/annurev-immunol-100311-102839
121. Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich A. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr. (2003) 142: 292-6. doi:10.1067/mpd.2003.110
122. Hazen MM, Woodward AL, Hofmann I, Degar BA, Grom A, Filipovich AH, et al. Mutations of the hemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis. Arthritis Rheum. (2008) 58: 567-70. doi:10.1002/art.23199
123. Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A, et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther. (2005) 7:R30-7. doi:10.1186/ar1453
124. Hermans IF, Ritchie DS, Yang J, Roberts JM, Ronchese F. CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J Immunol. (2000) 164: 3095-101. doi:10.4049/jimmunol.164.6.3095
125. + T cells in vivo. Proc Natl Acad Sci USA. (2006) 103: 147-52. doi:10.1073/pnas.0509054103
126. Terrell CE, Jordan MB. Perforin deficiency impairs a critical immunoregulatory loop involving murine CD8+ T cells and dendritic cells. Blood. (2013) 121: 5184-91. doi:10.1182/blood-2013-04-495309
127. Lykens JE, Terrell CE, Zoller EE, Risma K, Jordan MB. Perforin is a critical physiologic regulator of T-cell activation. Blood (2011) 118: 618-26. doi:10.1182/blood-2010-12-324533
128. Brisse E, Imbrechts M, Mitera T, Vandenhaute J, Wouters CH, Snoeck R, et al. Lytic viral replication and immunopathology in a cytomegalovirus-induced mouse model of secondary hemophagocytic lymphohistiocytosis. Virol J. (2017) 14: 240. doi:10.1186/s12985-017-0908-0